Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

Summary

Primary Objective: \- Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in predefined lesional skin in pediatric participants with moderate to severe atopic dermatitis (AD) treated with dupilumab. Secondary Objectives: * Evaluate changes in skin barrier function with TEWL assessed after STS in predefined lesional and non-lesional skin in pediatric participants with moderate to severe AD treated with dupilumab in reference to normal skin of healthy volunteers. * Evaluate time course of change in skin barrier function with TEWL assessed before and after STS in predefined lesional and non-lesional skin in pediatric participants with moderate to severe AD during dupilumab treatment phase and follow-up period in reference to normal skin of healthy volunteers.

Timeline

Start

2021-02-19

Primary completion

2022-09-07

Completion

2022-11-30

Publications

• Cork MJ, Ong PY, Danby SG, Byers RA, Matcher SJ, Katibi OS, Brown K, Andrew PV, Pinnock A, Poyner A, Johnson L, Gormley S, Hyde A, Ramirez-Gama M, Garcia S, Taylor PA, Bologna G, Praestgaard AH, Zahn J, Zhang A, Leung DYM. Dupilumab treatment restores epithelial barrier in nonlesional and lesional skin in children with atopic dermatitis. Ann Allergy Asthma Immunol. 2026 May;136(5):558-564.e3. doi: 10.1016/j.anai.2026.01.008. Epub 2026 Jan 27.

Drugs

Indications